Supplemental Figure I: Study design
Actovegin i.v. followed by Actovegin tablets
Screening and Randomization Efficacy follow-up Placebo i.v. followed by placebo tablets ≤7 days post stroke 6 months 6 months Subjects who had suffered ischemic stroke were randomized to receive either Actovegin or placebo in a 1:1 ratio within 5 to 7 days following the stroke onset. The trial consisted of a screening period (up to 6 days), followed by a randomized treatment period (up to 20 intravenous [i.v.] daily infusions, then tablets for the remainder of the 6-month treatment period), ending with a 6-month efficacy follow-up period (where subjects were allowed to undergo treatment in accordance with standard clinical practice). electrocardiogram. Data are n (%).
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*The odds ratio (95% CI) for cerebrovascular events on Actovegin compared to placebo was 2.09 (0.83, 5.26); р=0,124 suggesting this was not statistically significant (post-hoc analysis).
Randomization and masking Full Methods
Patients were randomized to receive either Actovegin or placebo in a 1:1 ratio, without stratification and using a block size of four, by means of a computerized central randomization system, IVRS/IWRS. Before dispensing treatment, investigators reviewed all eligibility criteria and provided the IVRS/IWRS with the patient number, date of birth, and gender. Based on this information, patients were assigned to a kit number determined by the program. The infusion and tablet bottles were labelled and masked with a kit number generated by the randomization. During double-blind treatment and until end of follow-up, all investigators and patients were masked to treatment assignment.
Per protocol (PP) analyses
The demographic and baseline characteristics for the PP analysis set were similar to those for the ITT set. The results of the ANCOVA for the PP analysis set (212 and 220 patients in the Actovegin and placebo groups respectively [196 and 202 respectively at 6 months) were supportive of the results of the primary analysis on the ITT set described: the LS mean (SE) change from baseline was -4.2 (0.60) for placebo and -6.4 (0.60) for Actovegin. The LS mean difference for Actovegin -placebo was -2.2, with an associated 95% CI (-3.9, -0.5), which was statistically significant in favour of Actovegin (p = 0.010).
Further Safety Results
Dyslipidemia was reported more frequently with Actovegin, compared with placebo during the study. All of these events were non-serious and did not lead to discontinuation from the study. Of note, the number of clinically significant chemistry laboratory values associated with cholesterol (low density lipoproteins) and triglycerides at month 6 was higher in the placebo group compared to Actovegin. Six (2.4%) deaths occurred in the placebo group and seven (2.8%) in the Actovegin group. All of the deaths were considered not related to the study medication. An overview of TEAEs is presented in Supplemental Table XI. The noticeable difference in AEs leading to discontinuation from the study was due to recurrent stroke. However, during double-blind treatment, 21 patients (14 in the Actovegin group and seven in the placebo group) experienced cerebrovascular events (ischemic stroke, intracerebral hemorrhage and transient ischemic attack [TIA] ). The odds ratio (95% CI) for cerebrovascular events on Actovegin compared to placebo was 2.09 (0.83, 5.26), suggesting this was not statistically significant (post-hoc analysis). Of these 21 patients, seven patients (2.8%) in the placebo group and 13 patients (5.2%) in the Actovegin group experienced recurrent ischemic stroke. Two patients in the placebo group and one patient in the Actovegin group had a fatal outcome as a result of this event; one patient in the Actovegin group experienced a fatal event of cerebral hemorrhage. Of seven patients in the placebo group, one patient experienced a non-serious cerebrovascular event, which was interpreted by the investigator as a transient ischemic attack. During the 6-month follow up, three patients in the placebo group and two patients in the Actovegin group discontinued due to recurrent ischemic stroke. Overall, 10 (4.0%) of 253 patients receiving placebo and 16 (6.4%) of 250 patients in the Actovegin group experienced cerebrovascular events. All cases of recurrent strokes were not related to the study medication (reported by investigators). A summary of TEAEs related to cerebrovascular events is presented in Supplemental Table XII. 
